Andrew Benjamin Nixon, PhD

Associate Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Wijkander, J., J. T. O’Flaherty, A. B. Nixon, and R. L. Wykle. “5-Lipoxygenase products modulate the activity of the 85-kDa phospholipase A2 in human neutrophils..” J Biol Chem 270, no. 44 (November 3, 1995): 26543–49. https://doi.org/10.1074/jbc.270.44.26543.

PMID
7592874
Full Text

Winkler, J. D., A. N. Fonteh, C. M. Sung, J. D. Heravi, A. B. Nixon, M. Chabot-Fletcher, D. Griswold, L. A. Marshall, and F. H. Chilton. “Effects of CoA-independent transacylase inhibitors on the production of lipid inflammatory mediators..” J Pharmacol Exp Ther 274, no. 3 (September 1995): 1338–47.

PMID
7562506
Scholars@Duke

Strum, J. C., A. B. Nixon, L. W. Daniel, and R. L. Wykle. “Evaluation of phospholipase C and D activity in stimulated human neutrophils using a phosphono analog of choline phosphoglyceride..” Biochim Biophys Acta 1169, no. 1 (July 21, 1993): 25–29. https://doi.org/10.1016/0005-2760(93)90077-m.

PMID
8334146
Full Text

Schmitt, J. D., A. B. Nixon, A. Emilsson, L. W. Daniel, and R. L. Wykle. “A facile synthesis of 1-O-alkyl-2-(R)-hydroxypropane-3-phosphonocholine (lyso-phosphono-platelet activating factor)..” Chem Phys Lipids 62, no. 3 (October 1992): 263–68. https://doi.org/10.1016/0009-3084(92)90063-u.

PMID
1468125
Full Text

Pages